ImmunoGen Inc.
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
639 articles about ImmunoGen Inc.
-
ImmunoGen Announces Proposed Public Offering of Common Stock - May 03, 2023
5/3/2023
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that it intends to offer and sell, subject to market and other conditions, $200 million of shares of its common stock in an underwritten public offering.
-
ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results
4/28/2023
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2023.
-
ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer
4/24/2023
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that Isabel Kalofonos has been appointed Senior Vice President and Chief Commercial Officer.
-
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2023 Operating Results
4/13/2023
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 28, 2023 to discuss its first quarter 2023 operating results.
-
ImmunoGen Announces Non-Dilutive Term Loan Financing for Up to $175 Million with Pharmakon Advisors
4/6/2023
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced it has entered into a term loan financing facility for up to $175 million with entities managed by Pharmakon Advisors, LP.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 03, 2023
4/3/2023
ImmunoGen, Inc. announced that on March 31, 2023, the Compensation Committee of the Company’s Board of Directors approved, in aggregate, grants of non-qualified stock option awards to purchase 106,600 shares of its common stock and restricted stock units covering 7,800 shares of its common stock to three new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended.
-
ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting
3/25/2023
ImmunoGen, Inc. announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who had been previously treated with bevacizumab will be presented by Dr. Robert Coleman in a plenary session on Saturday, March 25, at the SGO 2023 Annual Meeting in Tampa, Florida.
-
ImmunoGen Reports Recent Progress and 2022 Financial Results
3/1/2023
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter and year ended December 31, 2022.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 01, 2023
3/1/2023
ImmunoGen, Inc. announced that on February 28, 2023, the Compensation Committee of the Company’s Board of Directors approved, in aggregate, grants of non-qualified stock option awards to purchase 49,450 shares of its common stock and restricted stock units covering 15,200 shares of its common stock to three new employees under the ImmunoGen, Inc.
-
ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents
3/1/2023
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates, announced a global, multi-target license and option agreement whereby it granted Vertex Pharmaceuticals rights to conduct research using ImmunoGen's ADC technology to discover novel targeted conditioning agents for use with gene editing.
-
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences - February 22, 2023
2/22/2023
ImmunoGen, Inc. announced that the following presentations by Company management at upcoming investor conferences will be webcast: Cowen 43rd Annual Health Care Conference March 8 at 9:10am ET Barclays Global Healthcare Conference March 15 at 10:15am ET A webcast of each presentation will be accessible through the “Investors and Media” section of the Company’s website, www.immunogen.com.
-
ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results
2/15/2023
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Wednesday, March 1, 2023 to discuss its 2022 operating results.
-
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences - February 01, 2023
2/1/2023
ImmunoGen, Inc. announced that the following presentations by Company management at upcoming investor conferences will be webcast.
-
ImmunoGen Appoints Michael Vasconcelles, MD, as Executive Vice President, Research, Development, and Medical Affairs
1/4/2023
ImmunoGen, Inc. today announced that Michael Vasconcelles, MD, has been appointed Executive Vice President, Research, Development, and Medical Affairs.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 04, 2023
1/4/2023
ImmunoGen, Inc. announced that on December 29, 2022, and in connection with the previously announced appointment of Michael J. Vasconcelles, MD as ImmunoGen’s Executive Vice President, Research, Development, and Medical Affairs, the compensation committee of the Company’s Board of Directors approved grants of non-qualified stock option awards to purchase 960,000 shares of its common stock under the ImmunoGen, Inc.
-
ImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO Appointed
12/28/2022
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that Susan Altschuller, PhD, Senior Vice President and Chief Financial Officer, is on leave under the Family and Medical Leave Act and will not continue employment with ImmunoGen at the conclusion of her leave.
-
ImmunoGen Announces Webcast of Presentation and Q&A at the 41st Annual J.P. Morgan Healthcare Conference
12/27/2022
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that Mark Enyedy, President and CEO, will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation is scheduled for 3:45pm PT on January 10, 2023.
-
Biosion Announces Research Collaboration with ImmunoGen to Create Novel Antibody-Drug Conjugates
12/13/2022
Biosion USA, Inc., a global R&D biotechnology company, announced an exploratory research collaboration to create antibody-drug conjugates for the treatment of cancer with ImmunoGen, Inc., a leader in developing next generation ADCs.
-
ImmunoGen Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH
12/10/2022
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced initial safety and efficacy findings from dose-escalation and expansion cohorts of the Phase 1b/2 study of pivekimab sunirine in combination with Vidaza® and Venclexta® in patients with relapsed/refractory and frontline acute myeloid leukemia.
-
ImmunoGen entered into a clinical collaboration deal with Gilead Sciences Friday to evaluate the safety and efficacy of two drugs that, when used in concert, have the potential to treat AML.